Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nippon Shinyaku CoTSE:4516 +1.45%92 ROC (Joel Greenblatt) % is 12.12% as of Mar. 2026, which is 66% below its 10-year median of 36.01. GuruFocus rates TSE:4516 with a GF Score™ of 92/100 and a GF Value™ of 円4,832.18 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 981 Drug Manufacturers companies, Nippon Shinyaku Co ranks better than 78.08% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Nippon Shinyaku Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 12.12%.
The historical rank and industry rank for Nippon Shinyaku Co's ROC (Joel Greenblatt) % or its related term are showing as below:
TSE:4516'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 28.99 Med: 36.01 Max: 41.94
Current: 35.05
During the past 13 years, Nippon Shinyaku Co's highest ROC (Joel Greenblatt) % was 41.94%. The lowest was 28.99%. And the median was 36.01%.
TSE:4516's ROC (Joel Greenblatt) % is ranked better than 78.08% of 981
companies
in the Drug Manufacturers industry
Industry Median: 11.53
vs TSE:4516: 35.05
Nippon Shinyaku Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -0.90% per year.
Nippon Shinyaku Co (TSE:4516) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Nippon Shinyaku Co ROC (Joel Greenblatt) % Related Terms
Nippon Shinyaku Co ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Nippon Shinyaku Co's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4516 vs ZTS, UTHR: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Nippon Shinyaku Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nippon Shinyaku Co ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nippon Shinyaku Co's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Nippon Shinyaku Co's ROC (Joel Greenblatt) % falls into.
Nippon Shinyaku Co ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 12.12% mean?
Nippon Shinyaku Co (TSE:4516) has a ROC (Joel Greenblatt) % of 12.12% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Nippon Shinyaku Co and its competitors. This is 66% below median its historical median of 36.01. Over the past decade, Nippon Shinyaku Co's ROC (Joel Greenblatt) % has ranged from 28.99 to 41.94. According to the industry distribution chart, Nippon Shinyaku Co ranks #215 out of 981 companies in the Drug Manufacturers industry, placing it in the top 21.9%.
Is Nippon Shinyaku Co's ROC (Joel Greenblatt) % too high?
Nippon Shinyaku Co's current ROC (Joel Greenblatt) % of 12.12% is 66% below median its 10-year median of 36.01. Over the past 10 years, this metric has ranged from a low of 28.99 to a high of 41.94. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.53. Nippon Shinyaku Co's value of 12.12% is 5.1% above this industry median. Based on the distribution chart, Nippon Shinyaku Co ranks #215 out of 981 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Nippon Shinyaku Co has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nippon Shinyaku Co's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Nippon Shinyaku Co ranks #215 out of 981 companies for ROC (Joel Greenblatt) %. This places Nippon Shinyaku Co in the top 22% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.53. Nippon Shinyaku Co's value of 12.12% is 5.1% above this benchmark. Historically, Nippon Shinyaku Co's own ROC (Joel Greenblatt) % has ranged from 28.99 to 41.94 over the past decade. While the company's 10-year median is 36.01 vs. the industry median of 11.53, Nippon Shinyaku Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.53, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nippon Shinyaku Co's current ROC (Joel Greenblatt) % of 12.12% is 5.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Nippon Shinyaku Co and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nippon Shinyaku Co's current ROC (Joel Greenblatt) % is 12.12%, which is 66% below median its own 10-year median of 36.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nippon Shinyaku Co stock overvalued right now?
Based on GuruFocus' analysis, Nippon Shinyaku Co (TSE:4516) is currently considered Modestly Undervalued. The stock's GF Value™ is 円4,832.18, compared to a current price of 円4,048.00 — trading 16.2% below its estimated fair value. The current ROC (Joel Greenblatt) % is 12.12%, which is 66% below median its 10-year median of 36.01 and 5.1% above the Drug Manufacturers industry median of 11.53. Nippon Shinyaku Co's overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Nippon Shinyaku Co (TSE:4516), the current ROC (Joel Greenblatt) % is 12.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nippon Shinyaku Co (TSE:4516) Overvalued in 2026?
Based on GuruFocus' analysis, Nippon Shinyaku Co stock appears to be undervalued.
The current stock price of 円4,048.00 is trading 16.2% below its estimated GF Value™ of 円4,832.18.
GuruFocus considers Nippon Shinyaku Co to be Modestly Undervalued.
Key valuation signals for TSE:4516:
ROC (Joel Greenblatt) %: 12.12% (66% below median its 10-year median of 36.01)
GF Value™: 円4,832.18 vs. price of 円4,048.00 (16.2% below fair value)
Industry Position: 5.1% above the Drug Manufacturers median (#215 of 981)
No single metric tells the full story. See the TSE:4516 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nippon Shinyaku Co Ltd is engaged in the pharmaceuticals and functional food businesses. The Pharmaceuticals Business develops and sells treatments for urological disorders, blood cancer, rare and intractable diseases, and gynecological conditions. The Functional Food Business produces and sells health food ingredients, quality-stabilizing preservatives, protein preparations, and supplements. It generates the majority of its revenue from the Pharmaceuticals segment.
92GF Score
Get the complete analysis for TSE:4516
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4516 has been successfully added to your 
